V. Margulis1,2,3,4,5,6,7,8,9, Yair Lotan1,2,3,4,5,6,7,8,9, Pierre I. Karakiewicz1,2,3,4,5,6,7,8,9, Yves Fradet1,2,3,4,5,6,7,8,9, Raheela Ashfaq1,2,3,4,5,6,7,8,9, Umberto Capitanio1,2,3,4,5,6,7,8,9, F. Montorsi1,2,3,4,5,6,7,8,9, Boris Hadaschik1,2,3,4,5,6,7,8,9, Matthew E. Nielsen1,2,3,4,5,6,7,8,9, Stefan C. Müller1,2,3,4,5,6,7,8,9, J. Rigaud1,2,3,4,5,6,7,8,9, Lukas C. Heukamp1,2,3,4,5,6,7,8,9, George J. Netto1,2,3,4,5,6,7,8,9, Seth P. Lerner1,2,3,4,5,6,7,8,9, Arthur I. Sagalowsky1,2,3,4,5,6,7,8,9, S.F. Shariat1,2,3,4,5,6,7,8,9
1Affiliations of authors: Department of Urologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX (VM)
2Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada (PIK, UC)
3Centre de recherche en cancérologie de l’Université Laval, L’Hôtel-Dieu de Québec, CHUQ, Québec, Canada (YF, JR)
4Department of Urology (MEN, LCH) and Department of Pathology (GN), Johns Hopkins Hospital, Baltimore, MD
5Department of Urology (PJB, SCM) and Department of Pathology (MEN, LCH), Rheinische Friedrich-Wilhelms Universität, Bonn, Germany
6Department of Urology (YL, AIS, SFS) and Department of Pathology (RA), University of Texas Southwestern Medical Center, Dallas, TX
7Department of Urology, Ludwig-Maximilians-Universität München, Munich, Germany (PJB)
8Department of Urology, Vita-Salute University, Milan, Italy (UC, FM)
9Scott Department of Urology, Baylor College of Medicine, Houston, TX (SPL)
